New Horizon Aircraft Ltd. (HOVR) is an advanced aerospace OEM developing the Cavorite X7, a seven-seat hybrid-electric eVTOL aircraft aimed at Regional Air Mobility. Its hybrid propulsion system combines vertical takeoff and landing with fixed-wing cruising, which should deliver longer range and higher speeds than most battery-only eVTOL designs while sidestepping the runway needs of conventional aircraft. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
This setup gives the X7 a clear role in longer regional missions such as emergency medical services, regional passenger travel, remote access, and disaster response rather than short urban hops. Partnerships with suppliers like BETA for flight controls and Marshall Aerospace for modeling are meant to keep development moving without excessive capital burn. The main risk in the medium term is still execution, since the company remains pre-revenue and needs to hit certification and production milestones to turn positioning into lasting value.
The biggest near-term driver is finishing and testing the full-scale demonstrator. Management has pointed to completion around the end of the first calendar quarter of 2027, with testing starting in conventional takeoff mode before moving to vertical operations. Progress here will likely matter more to investors than quarterly financials alone.
Work with Transport Canada on certification is another focus, along with broader industry efforts through the FAA’s eVTOL Integration Pilot Program. Other potential catalysts include turning existing LOIs into firm orders, possible defense interest, and further progress on all-weather IFR and icing capabilities backed by the INSAT grant. On the analyst side, coverage is still limited but positive: Jones Trading started with a Buy and $18 target in February 2026, and D. Boral Capital reaffirmed a Buy with an $11 target in April 2026. Consensus reflects a “Strong Buy,” with average targets in the mid-to-high single digits and a wide range from about $3 to above $18, highlighting the milestone-driven nature of the name.
New Horizon’s progress is tied to how the broader advanced air mobility sector matures. Regulatory frameworks, infrastructure, and public acceptance will all play a role in when the X7 can enter commercial service. As a pre-revenue developer, access to capital is critical, so interest rates, risk appetite, and dilution terms remain important external factors.
Defense and emergency-services procurement could provide additional support, given growing interest in runway-independent, longer-range aircraft. Inflation and supply-chain costs affect prototyping and future economics, while non-dilutive grants like the INSAT program help limit share-count growth.
As 2026 winds down, HOVR heads into 2027 focused on the demonstrator build and early flight tests, supported by its engineering partnerships. Longer term, the case depends on converting the sizable LOI book into actual orders and advancing toward type certification.
Key themes include unproven margin sustainability at scale, competition from larger eVTOL players and helicopter makers, capital allocation between grants and equity raises, and regulatory developments in Canada and the U.S. Analyst targets currently show optimism around these drivers, but they remain external forecasts sensitive to execution, financing, and certification risks.
Tickeron’s Trend Prediction Engine helps me gauge whether a stock like HOVR may trend bullish, bearish, or sideways over the next week or month. It offers searchable predictions, historical context, and alerts that complement my review of milestone timelines and analyst targets. I find it useful for adding a data-driven perspective on short-term momentum in development-stage names.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
HOVR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HOVR as a result. In 41 of 50 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for HOVR turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In 21 of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOVR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for HOVR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.346) is normal, around the industry mean (4.932). P/E Ratio (-1.688) is within average values for comparable stocks, (16.814). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (18.330).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. HOVR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOVR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry AerospaceDefense